

M42 joins hands with Abbott to advance early cancer detection capabilities in UAE

July 23, 2026 | News

Combining global healthcare innovation with national diagnostic expertise



M42's National Reference Laboratory (NRL), a leading provider of diagnostic services in the region, has entered into a strategic partnership with Abbott to support the introduction of innovative early cancer detection solutions in the UAE, using advanced diagnostic solutions based on biomarker testing and multi-marker algorithm-driven analyses to strengthen the country's diagnostic capabilities and support earlier, more informed clinical decision-making.

As part of the agreement, NRL and Abbott will work together to implement innovative early cancer detection solutions designed to support earlier identification of cancer and more informed clinical decision-making.

The initial phase will focus on a pilot programme aimed at reducing cancer incidence and mortality while improving patient outcomes across the UAE, ahead of broader implementation, helping establish the foundations for wider adoption across the healthcare ecosystem.

The partnership marks a significant step in advancing access to innovative diagnostic technologies in the UAE, where the Ministry of Health and Prevention has identified early detection and screening as critical components of the UAE's National Cancer Control Programme. Guided by the UAE Vision 2031 agenda, these efforts are designed to help close gaps in the current system, strengthen the country's oncology ecosystem, and position the UAE as a regional benchmark for equitable, high-quality cancer care.

As part of the agreement, NRL and Abbott will work together to implement innovative early cancer detection solutions designed to support earlier identification of cancer and informed clinical decision-making. The initial phase will focus on a pilot program ahead of broader implementation, helping establish the foundations for wider adoption across the healthcare ecosystem.